secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001213900-23-024301
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reports Q4 2022 net loss $8.2M; FDA grants Type A meeting for DefenCath resubmission
--------------------------------------------------------------------------------

- Q4 2022 net loss $8.2M ($0.20/shr) vs $7.8M loss in Q4 2021; full-year net loss $29.7M ($0.74/shr).
- Cash and short-term investments $58.8M at Dec 31, 2022; $7.2M raised via ATM in Q1 2023.
- FDA granted Type A meeting in mid-April to discuss DefenCath NDA resubmission; CMO corrective actions completed.
- Agreement with Siegfried AG (Hameln, Germany) as backup CMO for DefenCath manufacturing.
- Promoted Erin Mistry to EVP/Chief Commercial Officer and Dr. Tushar Mukherjee to SVP/Head of Technical Operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/0001213900-23-024301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/ea176049-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-024301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer